-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Metabolomic determination of pathogenesis of late-onset preeclampsia.
Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH.
J Matern Fetal Neonatal Med 2017;30:658-64. pdf -
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H.
N Engl J Med 2016;374:434-43. pdf -
Validation of metabolomic models for prediction of early-onset preeclampsia.
Bahado-Singh RO, Syngelaki A, Akolekar R, Mandal R, Bjondahl TC, Han B, Dong E, Bauer S, Alpay-Savasan Z, Graham S, Turkoglu O, Wishart DS, Nicolaides KH.
Am J Obstet Gynecol 2015;213:530.e1-530.e10. pdf -
Maternal serum anti-Mallerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC.
J Matern Fetal Neonatal Med 2015;28:865-8. pdf -
First-trimester metabolomic detection of late-onset preeclampsia.
Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K.
Am J Obstet Gynecol 2013;208:58. pdf -
Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013;26:733-7. -
Metabolomics and first-trimester prediction of early-onset preeclampsia.
Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K.
J Matern Fetal Neonatal Med 2012;25:1840-7. pdf -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH.
Prenat Diagn 2009;29:753-60. -
Maternal serum activin at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2009;25:320-7. -
Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:622-6. -
First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction.
Ong CY, Liao AW, Munim S, Spencer K, Nicolaides KH.
J Matern Fetal Neonatal Med 2004;15:176-80. -
Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia.
Sebire NJ, Roberts L, Noble P, Wallace E, Nicolaides KH.
BJOG 2000;107:795-7.